Form 4: Cartesian Therapeutics Chief Scientific Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher M. Jewell, Chief Scientific Officer of Cartesian Therapeutics, sold a portion of his shares to cover withholding tax obligations and broker fees related to vesting restricted stock units.
Summary
- Christopher M. Jewell, the Chief Scientific Officer of Cartesian Therapeutics, sold 1,264 shares of common stock on January 3, 2025, at a price of $16.7219 per share.
- He then sold an additional 1,286 shares on January 6, 2025, at a price of $16.8322 per share.
- These sales were made to satisfy withholding tax obligations and cover broker fees associated with the vesting of restricted stock units.
- Following these transactions, Jewell's direct ownership of Cartesian Therapeutics common stock decreased from 56,040 to 53,490 shares.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment about the company's performance or future prospects.
Industry Context
This is a routine filing related to insider transactions, which is common for executives who receive stock-based compensation. It does not indicate any specific trend or issue within the biotechnology industry.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across all industries, including biotechnology.
- These transactions are typically disclosed through SEC Form 4 filings, which are standard for publicly traded companies.
- The volume of shares sold is relatively small compared to the total outstanding shares, suggesting it is a routine transaction rather than a significant change in ownership.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are routine and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Sale of 1,264 shares of common stock at $16.7219 per share. |
| 01/06/2025 | Sale of 1,286 shares of common stock at $16.8322 per share. |
| 01/07/2025 | Date of signature of the Form 4 filing. |
Keywords
Cartesian Therapeutics, insider trading, stock sale, Form 4, Christopher M. Jewell, Chief Scientific Officer, restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.